Efficacy and tolerability of a new non-extrafine formulation of beclomethasone HFA-134a in patients with asthma: Comparison with beclomethasone CFC

Clinical Drug Investigation

Volumn 22, Issue 10, 2002, Pages 653-665

  Rocca Serra, Jean Paul ^a   Vicaut, Eric ^b   Lefrancois, Gerard ^c   Umile, Alberto ^d  

^a HÔPITAL SAINT JOSEPH   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Chiesi SA   (France)

^d Chiesi Group   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATININE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; HYDROCORTISONE; LONG ACTING DRUG; NEDOCROMIL; NORFLURANE; PROPELLANT; THEOPHYLLINE;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHITIS; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; CREATININE URINE LEVEL; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG TOLERABILITY; EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HOARSENESS; HUMAN; HYDROCORTISONE URINE LEVEL; LARYNGITIS; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SORE THROAT; SPIROMETRY; SYMPTOMATOLOGY; TRACHEITIS; WAKEFULNESS;

EID: 0036397509     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222100-00002     Document Type: Article

References (26)

1. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. Bethesda (MD): National Institute of Health; 1995. NIH publication No. 95-3659, 1995
2. Nathan R, Pinnas J, Schwartz H, et al. A six-month, placebocontrolled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma. Ann Allergy Asthma Immunol 1999; 82: 521-9
3. Beasley R, Crane J, Lai C, et al. Prevalence and etiology of asthma. J Allergy Clin Immunol 2000; 105: S466-72
4. Woodruff P, Fahy J. Asthma: prevalence, pathogenesis, and prospects for novel therapies. JAMA 2001; 286: 395-8
5. Secretariat of the Montreal Protocol. Montreal protocol on substances that deplete the ozone layer- 1987 [online]. Available from URL: http://www.montrealprotocol.org [Accessed 2001 Sep 20]
6. Committee for Proprietary Medicinal Products. The note for guidance on replacement CFCs in metered dose inhalation products. European Union CPMP guidelines. III/5462/93 Rev. 1. 1993
7. Leach C. Approaches and challenges to use freon propellant replacements. Aerosol Sci Technol 1995; 22: 328-34
8. Alexander DJ. Safety of propellants. J Aerosol Med 1995; 8 Suppl. 1: S29-34
9. June D, Schultz R, Miller N. A conceptual model for the delivery of pressurized metered-dose hydrofluoroalkane-based inhalation aerosols. J Pharm Technol 1994; 18: 40-52
10. Leach CL, Davidson PJ, Boudreau RJ, et al. The improved airway targeting with the CFC-free HFA beclomethasone metered-dose inhaler compared with CFC beclornethasone. Eur Resp J 1998; 12 (6): 1346-53
11. Davies R, Stampone P, O'Connor B. Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir Med 1998; 92 Suppl A: 23-31
12. Brambilla G, Ganderton D, Garzia R. et al. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int J Pharm 1999; 186: 53-61
13. Derom E. Pauwels R. Bioequivalence of inhaled drugs. Eur Respir J 1995; 8: 1634-6
14. Fuller R, Hallett C, Dahl R. Assessing equivalence of inhaled drugs. Respir Med 1995; 89: 525-7
15. Rogers D, Ganderton D. Determining equivalence of inhaled medications. Respir Med 1995; 89: 253-61
16. Jones B, Jarvis P, Lewis J, et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996; 313: 36-9
17. Snell N. Assessing equivalence of inhaled products. J Pharm Pharmacol 1997; 49 Suppl. 3: 55-60
18. Steinijans VW, Neuhauser M, Hummel T, et al. Asthma management: the challenge of equivalence. Int J Clin Pharmacol Ther 1998; 36: 117-25
19. Gross G, Thompson P, Chervinski P, et al. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 μg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 μg, for the treatment of moderate asthma. Chest 1999; 115: 343-51
20. Demedts M, Cohen R, Hawkinson R. Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers. Int J Clin Pract 1999; 53: 331-8
21. Bahous J, Cartier A, Malo J. Monitoring of peak expiratory flow rates in subjects with mild airway hyperexcitability. Bull Eur Physiopathol Respir 1985; 21: 25-30
22. Josephs L, Gregg I, Mullee M, et al. Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma. Am Rev Respir Dis 1989; 140: 350-7
23. Ryan G, Latimer K, Dolovich J, et al. Bronchial responsiveness to histamine: relationship to diurnal variation of peak flow rate, improvement after bronchodilator and airway calibre. Thorax 1982; 37: 423-9
24. Matthys H, Nowak D, Hader S, et al. Efficacy of chlorofluorocarbon-free beclomethasone dipropionate 400 mcg is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 mcg for the treatment of moderate asthma. Respir Med 1998; 92 (Suppl A): 17-22
25. Acerbi D, Deroubaix X, De Bruyn S, et al. In vitro-in vivo correlation study of three metered dose inhalers of beclomethasone dipropionate. Resp Drug Delivery 2000; 7: 365-8
26. Acerbi D. Daley Yates PT, et al. Pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients. Resp Drug Delivery 2002;8: 89-91